Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases in the United States, Europe, and internationally. Its lead product is RUCONEST, a recombinant C1 esterase inhibitor for acute attacks in adult and adolescent patients with hereditary angioedema (HAE). The company also develops Joenja (leniolisib), an oral small molecule PI3K inhibitor for activated phosphoinositide 3-kinase delta syndrome, and has a development collaboration and license agreement with Novartis. Incorporated in 1988, Pharming Group N.V. is headquartered in Leiden, the Netherlands.
AstraZeneca Invests $2B in Summit Therapeutics; Sangoma to Be Acquired for $204M
AstraZeneca announced a $2B equity investment in Summit Therapeutics and a clinical collaboration to develop new cancer treatments, sending Summit shares up 24%. Under the deal, AstraZeneca will purchase convertible preferred shares at a conversion price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. Sangoma Technologies shares soared 35% after the company agreed to be acquired by an affiliate of BRC Group Holdings in a transaction valuing the firm at approximately $204M in enterprise value, with shareholders receiving $4.925 in cash plus 0.04767 of a BRC share per Sangoma share, implying total consideration of $5.225 per share. Navitas Semiconductor jumped 14% after saying it was selected by the U.S. federal government to develop next-generation 10 kV silicon carbide power semiconductor technology under the Army's ALATTIS program. Pharming shares slipped 2% after CEO and executive director Fabrice Chouraqui stepped down with immediate effect, with Chief Commercial Officer Leverne Marsh and CFO Kenneth Lynard appointed interim co-CEOs.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
AZN.LSE · Capital · Positive Announced a $2B equity investment in Summit Therapeutics plus a clinical collaboration to develop new cancer treatments.
NVTS · Technology · Positive Selected by the U.S. federal government to develop next-generation 10 kV silicon carbide power semiconductor technology under the Army's ALATTIS program.
PHARM.AS · Capital · Negative CEO and executive director Fabrice Chouraqui stepped down with immediate effect, with interim co-CEOs appointed.
SANG · Capital · Positive Agreed to be acquired by a BRC Group Holdings affiliate at $5.225 per share, a 35% share jump.
RILY · Capital · Positive BRC Group Holdings affiliate is acquiring Sangoma Technologies in a $204M enterprise-value deal, paying cash plus BRC shares.
Pharming CEO Fabrice Chouraqui steps down; interim co-CEOs named
Pharming Group N.V. announced that Chief Executive Officer and Executive Director Fabrice Chouraqui has stepped down with immediate effect by mutual agreement with the Board of Directors. The Board has appointed Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard as Interim Co-CEOs, with Marsh leading patient-focused operations and Lynard leading global corporate functions, and has begun a formal search for a permanent successor. The company said the Board and Chouraqui concluded their views on how to advance Pharming's strategy were not sufficiently aligned following discussions about executing its strategic priorities for the next phase. Chairman Richard Peters said the immediate priority is ensuring continuity across leadership while maintaining focus on executing Pharming's strategy and its commitment to patients, and the company said its strategy, pipeline and commitment to patients remain unchanged. Pharming said it and Chouraqui will not comment further beyond this announcement to support an orderly transition process.
FDA Approves Pharming's Joenja for Children Aged 4 to 11 With APDS
The US FDA has approved Pharming Group's Joenja, also known as leniolisib, for children between the ages of four and 11 with a rare genetic immune system disorder. The treatment was previously approved in 2023 for individuals 12 years and older with activated phosphoinositide 3-kinase delta syndrome, or APDS. The approval was based on safety and pharmacokinetic data from a single-arm, open-label study. Individuals with APDS suffer from recurrent infections, especially in the sinuses, ears, and respiratory tract, and also develop enlarged lymph nodes, tonsils, and spleen.
Biotech & Genomic Medicine › Rare Disease ▲Regulation
PHARM.AS · Regulation · Positive FDA approves Joenja (leniolisib) for children aged 4-11 with APDS, expanding the label to a younger patient population.
Pharming Group announced the commercial launch of Joenja (leniolisib) in Japan for adults and children aged 4 years and older with activated PI3K delta syndrome, following its inclusion in the NHI price list. Joenja, an oral PI3Kd inhibitor, was approved based on results from a randomized, placebo-controlled Phase III trial that met its coprimary endpoints, showing statistically significant improvements in immune function. Pharming CFO Leverne Marsh called the launch a major milestone in expanding access to Joenja globally, particularly for younger patients in Japan who previously had no approved treatment options. The approval was granted earlier this year by Japan's Ministry of Health, Labour and Welfare, with OrphanPacific, Inc. serving as the local marketing authorization holder and distributor partner. Pharming shares closed Wednesday at $11.83, down 3.27%, and were up 3.13% at $12.20 in overnight trading.
Levi & Korsinsky Investigates Pharming Group Over Securities Claims After Stock Drop
Levi & Korsinsky has launched an investigation into Pharming Group concerning potential securities law violations. The investigation follows a 22% drop in Pharming Group stock on July 30, 2026, after the company reported second-quarter revenue of $90.2 million, down 3% year-over-year, and cut its full-year 2026 revenue guidance to $375-$395 million from $405-$425 million. The revenue shortfall was primarily driven by a 10% decline in sales of its legacy hereditary angioedema therapy RUCONEST to $72.3 million, while Joenja revenue rose 40% to $17.9 million. The firm is examining whether Pharming Group and certain officers failed to adequately disclose competitive and demand pressures affecting RUCONEST prior to the announcement. Investors who suffered losses are encouraged to contact the firm for a free case evaluation.
Pharming Group cuts 2026 revenue outlook to $375–$395 million after second-quarter revenue falls 3%
Pharming Group lowered its 2026 revenue forecast to a range of $375 million to $395 million after second-quarter revenue declined 3% to $90.2 million. The company also reduced its operating-expense forecast by $15 million to $315 million to $320 million, while expecting RUCONEST sales to stabilize and resume growth in the second half of 2026. Joenja remained the growth driver, with second-quarter revenue up 40% to $17.9 million, and management expects high-30% Joenja revenue growth in 2026. Pharming is advancing launches in Germany and Japan, pursuing additional pediatric doses in the U.S., and expects fourth-quarter Phase II results for leniolisib in broader primary immunodeficiency conditions, including CVID, which could represent an addressable population up to 40 times larger than APDS. Despite positive operating profit, cash and marketable securities declined to $159.5 million at quarter-end.
Pharming Group N.V. held its second-quarter 2026 earnings conference call. The call featured prepared remarks from company executives followed by a question-and-answer session with analysts. No specific financial figures or forward-looking statements were disclosed in the transcript provided.
Netherlands
United States
United Kingdom
Canada